The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
OBJECTIVE
Programmed death-1 (PD-1), an important immunosuppressive molecule, plays a key role in tumor-cell-mediated immune escape. In the present study, we evaluated the effect of PD-1 gene polymorphisms on the risk of developing epithelial ovarian cancer (EOC) and patients' outcomes.


METHODS
A case-control study was performed in 620 EOC patients and 620 control women. Survival data were available for 258 patients who received platinum-based chemotherapy after cytoreductive surgery.


RESULTS
There were significant differences in the genotype and allele distribution frequencies of the PD-1.1 A/G between cases and controls (P=0.028 and P=0.02, respectively). Compared with the AA genotype, AG and GG genotypes may significantly decrease the risk of developing EOC (OR=0.71, 95%CI=0.54-0.94; OR=0.68, 95%CI=0.50-0.94, respectively). We did not find a significant difference in the genotype distribution frequency of the PD-1.5 C/T between cases and controls (P=0.096), but the frequency of T alleles was significantly lower in the EOC cases than that in the controls (P=0.033). Compared to the carriers with C alleles, the carriers with T alleles were at a significantly decreased risk of developing EOC (OR=0.82, 95%CI=0.69-0.98). Survival analysis showed that the two polymorphisms were not associated with patients' outcomes.


CONCLUSIONS
PD-1 gene polymorphisms may be involved in the development of EOC, but not associated with its clinical outcome in EOC patients among northern Chinese women.
Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China. Electronic address: lykx1962@yahoo.com.cn.
Yan
Y
Li
Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
Hui-Lan
HL
Zhang
Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
Shan
S
Kang
Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
Rong-Miao
RM
Zhou
Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
Na
N
Wang
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D002681:China; D065426:Cytoreduction Surgical Procedures; D018572:Disease-Free Survival; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000628:therapy; D017671:Platinum Compounds / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D061026:Programmed Cell Death 1 Receptor / Q000235:genetics*; D012307:Risk Factors; D015996:Survival Rate; D055815:Young Adult
D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D017671:Platinum Compounds; D061026:Programmed Cell Death 1 Receptor
Clinical outcome; Epithelial ovarian cancer; PD-1; Polymorphisms; Risk